Savara Pharmaceuticals Lands $10,000,000 New Round

  • Feed Type
  • Date
    10/6/2014
  • Company Name
    Savara Pharmaceuticals
  • Mailing Address
    900 S. Capital of Texas Highway Austin, TX 78746 USA
  • Company Description
    Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
  • Website
    http://www.savarapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Savara will use the additional financing to support the continued development of AeroVanc for people with CF who often struggle with persistent MRSA infection. In addition, the financing adds to our resources for corporate development as we look to expand our pipeline to prepare for Savara’s next stage of growth.
  • M&A Terms
  • Venture Investor

Trending on Xconomy